Resmed appoints Salli Schwartz as Chief Investor Relations Officer to lead global investor relations and enhance shareholder engagement.
Quiver AI Summary
ResMed has appointed Salli Schwartz as the new Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience from roles in finance at health tech and financial services companies, most recently serving as Head of Investor Relations at Illumina, Inc. In her position at ResMed, she will lead the global investor relations function and report directly to CEO Mick Farrell. Schwartz has a strong background in managing investor communications and capital efficiency, having previously held key roles at MSCI, Inc., and Moody's Corporation. She expressed enthusiasm about joining ResMed during a pivotal time in the company's strategy aimed at enhancing global sleep and breathing health. ResMed is dedicated to delivering innovative health technologies that empower individuals worldwide to achieve better health outcomes.
Potential Positives
- Appointment of Salli Schwartz as Chief Investor Relations Officer adds significant expertise in investor engagement, which can enhance shareholder communications and confidence.
- Schwartz's extensive experience in health tech and financial services positions her to effectively support Resmed's strategic goals and improve capital efficiency.
- The announcement aligns with Resmed's 2030 strategy, indicating a strong commitment to driving shareholder value and expanding health technologies globally.
Potential Negatives
- Appointment of a new Chief Investor Relations Officer might indicate previous issues in investor relations or a need for stronger communication strategies regarding corporate strategy and financial performance.
- Potential oversight in not addressing how Schwartz’s previous experience at Illumina and MSCI will specifically translate to Resmed’s unique challenges and needs.
- Announcement could be seen as a response to shareholder pressures, which might suggest underlying concerns about current performance or future direction of the company.
FAQ
Who is the new Chief Investor Relations Officer at Resmed?
Salli Schwartz has been appointed as Chief Investor Relations Officer of Resmed as of April 21, 2025.
What experience does Salli Schwartz bring to Resmed?
Salli Schwartz brings over two decades of finance experience from health tech and financial services organizations, including Illumina and MSCI.
What is the role of Chief Investor Relations Officer?
The Chief Investor Relations Officer leads global investor relations, managing communications and engagement with shareholders regarding corporate strategy and financial performance.
How does Resmed aim to empower individuals through its technologies?
Resmed strives to empower 500 million people worldwide to achieve their full health potential through better sleep and breathing health.
What is Resmed’s vision for healthcare technology?
Resmed envisions creating life-changing health technologies that make home healthcare more accessible, personalized, and effective globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RMD Congressional Stock Trading
Members of Congress have traded $RMD stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 01/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RMD Insider Trading Activity
$RMD insiders have traded $RMD stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chief Executive Officer) has made 0 purchases and 5 sales selling 40,710 shares for an estimated $9,527,849.
- KAUSHIK GHOSHAL (Chief Commercial Officer, SaaS) has made 0 purchases and 5 sales selling 18,858 shares for an estimated $4,477,282.
- PETER C FARRELL has made 0 purchases and 6 sales selling 12,000 shares for an estimated $2,829,880.
- JUSTIN LEONG (Chief Product Officer) sold 6,160 shares for an estimated $1,497,415
- BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 6,000 shares for an estimated $1,412,190.
- WITTE JAN DE sold 796 shares for an estimated $198,052
- MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 6 sales selling 410 shares for an estimated $97,201.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RMD Hedge Fund Activity
We have seen 415 institutional investors add shares of $RMD stock to their portfolio, and 335 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GREENVALE CAPITAL LLP removed 700,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $160,083,000
- BLACKROCK, INC. added 696,843 shares (+5.8%) to their portfolio in Q4 2024, for an estimated $159,361,025
- MORGAN STANLEY removed 601,193 shares (-13.4%) from their portfolio in Q4 2024, for an estimated $137,486,827
- INVESCO LTD. added 566,046 shares (+32.2%) to their portfolio in Q4 2024, for an estimated $129,449,059
- COATUE MANAGEMENT LLC removed 473,179 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $108,211,305
- BANK OF AMERICA CORP /DE/ added 454,964 shares (+114.8%) to their portfolio in Q4 2024, for an estimated $104,045,717
- MARSHALL WACE, LLP removed 395,621 shares (-98.1%) from their portfolio in Q4 2024, for an estimated $90,474,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RMD Analyst Ratings
Wall Street analysts have issued reports on $RMD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 03/05/2025
- UBS issued a "Buy" rating on 01/31/2025
- KeyBanc issued a "Overweight" rating on 01/31/2025
To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.
$RMD Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 4 analysts offer price targets for $RMD in the last 6 months, with a median target of $255.0.
Here are some recent targets:
- Anthony Petrone from Mizuho Securities set a target price of $265.0 on 04/16/2025
- An analyst from Stifel Nicolaus set a target price of $240.0 on 03/05/2025
- Adam Maeder from Piper Sandler set a target price of $260.0 on 01/31/2025
Full Release
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD ), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO.
Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company’s investor engagement strategy, representing the company’s response to shareholders’ perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina’s Corporate Social Responsibility Executive Steering Committee and its Transformation Office.
“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Farrell. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”
Prior to Illumina, Schwartz served as Head of Investor Relations and Treasurer at MSCI, Inc., where she managed investor communications as well as a portfolio of over $2 billion in cash and short-term investments, and more than $4 billion in high-yield debt. She was also a member of MSCI’s Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee. Earlier in her career, Schwartz held multiple roles at Moody's Corporation, including Global Head of Strategic Capital Management and Treasurer, and Global Head of Investor Relations and Communications. She also worked in corporate strategy, corporate treasury, and FP&A with Citigroup Inc.
“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at
Resmed.com
and follow @Resmed.
For Media:
|
For Investors:
|
|
Kristen Handley Slater | Mike Ott or Wendy Wilson | |
[email protected] | [email protected] |